Scleroderma Mask Face Syndrome is a characteristic presentation that occurs when scleroderma enters the sclerotic phase of skin lesions. It is characterized by damage to the facial skin, which becomes more thickened, resulting in the disappearance of normal facial lines, a stereotyped face, a smaller nasal tip, an atrophied nose, thinner, inwardly retracted lips, perioral folds, and a reduced degree of mouth opening, known as masked face syndrome. Scleroderma is a connective tissue disease that can involve various organ systems throughout the body, mainly manifesting as sclerosis of the skin and internal organs. The cause of the disease is not clear, but it is mainly caused by an increase in collagen synthesis and secretion by fibroblasts in the body, which usually affects the fingers, face, forearms and other parts of the body. The characteristic manifestation of facial skin is the masked face syndrome. The natural course of scleroderma is highly variable. Early diagnosis and treatment can help prevent disease progression. The principle of treatment is vasodilatation, antifibrosis, immunosuppression and immunomodulation, but there is no specific drug at present. Scleroderma patients are advised to consult the rheumatology and immunology department in a timely manner, under the guidance of the doctor for standardized treatment and regular follow-up.